Topic: Epigenetic Factors and Mechanisms in Cancer Drug Resistance

Deregulated epigenetic mechanisms play an essential role in both cancer development and resistance to cancer drugs. The discovery of the epigenetic modification and modulation of DNA (by methylation) and histone proteins (by acetylation, methylation, etc.) has paved the way for a deeper understanding of drug resistance processes and the successful development of new cancer therapies. Epigenetic factors such as DNA methyltransferases, DNA demethylases, histone deacetylases, histone methyltransferases, histone demethylases, and reader proteins (BETs) are well-established factors crucial in cancer biology, serving as valuable targets for anticancer drugs. Moreover, the identification and evaluation of oncogenic or tumor-suppressing non-coding RNAs (e.g., miRNAs, lncRNAs, circRNAs, etc.) as epigenetic modifiers of genes and their transcripts with distinct implications for anticancer drug response has become another prolific and important field of cancer research.

This Special Issue aims to encapsulate the latest developments and research findings in the rapidly evolving field of cancer epigenetics, offering insights vital for understanding and overcoming cancer drug resistance. We welcome original research articles, review articles, case reports, and meta-analyses.